Oncology

 

Translational Oncology 中文 (CN version)


Translational Oncology

  • Biomarker discovery
  • Human tumor bank
  • Mouse clinical trial
  • 67 PDX-derived primary cancer cell lines
  • Drug-resistant PDX models
  • Combination therapy platform including radiation
  • World leading genome sequencing and bioinformatics capability

 

Tissue based biomarker capability

20150410-24

 

Human Tissue Bank at WuXi

1123-8

 

Combination therapy platform including radiation

  • Breast cancer model: BR-05-0028
  • MLN4924, a NAE inhibitor, showed synergetic effect with focal radiation

1125-1

 

PDX derived human cancer cell lines (PCC)

  • 67 human cancer cell lines generated from PDX models
    • With matched PDX models
    • Cancer stem cell (CSC) features
    • 64/67 form xenografts in mice which recapitulate pathology of the original patient tumor
    • Genomic profiling data available
  • List of human cancer lines from PDX

1125-2

 

Drug-resistant PDX

  • Resistance was induced by repeated treatment
  • Genomic profiling data available for erlotinib and crizotinib resistant NSCLC models

20150414-7

 

Erlotinib resistant Lung cancer PDX harboring EGFRL858R

  • LU-01-0055 PDX harboring EGFRL858R
  • Sensitive to erlotinib
  • Erlotinib resistant LU- 01-0055R
  • Afatinib overcame the erlotinib resistance

20150410-11

 

Mouse trial in PDX models:
WuXi Oncology has conducted multiple mouse trials in two following categories, which will serve as proof-of-concept evidence for preclinical pharmacology study.

1125-3

1125-4